Chinese COVID-19 vaccine candidate shows promise in human trial

  • Chinese COVID-19 vaccine candidate shows promise in human trial

Chinese COVID-19 vaccine candidate shows promise in human trial

A division of Chinese state-run Sinopharm Group Co Ltd that is developing two COVID-19 vaccines is offering them for free to Chinese students going overseas for higher studies, the Wall Street Journal reported on Wednesday.

In mid-August, Russia released the world's first coronavirus vaccine approved for public use, Sputnik V. However, scientists worldwide have cast doubt on the vaccine, as it was registered before the results of phase 3 studies were made available.

The registered vaccine, EpiVacCorona, was developed at a research centre in the Siberian city Novosibirsk, said Putin.

Putin said that Deputy Prime Minister Tatyana Golikova and the head of Russia's consumer safety watchdog Anna Popova have both received the EpiVacCorona vaccine as part of clinical trials.

One of China's leading COVID-19 vaccine candidates, called BBIBP-CorV, was shown to be safe and elicited immune response in a small early-phase human trial, researchers said on Friday. "We are continuing to cooperate with our foreign partners and will promote our vaccine overseas", Putin said.

Russian Federation has given regulatory approval to a second Covid-19 vaccine, named "EpiVacCorona", after early-stage studies. "Unlike with the first Russian vaccine, Sputnik V, which is an adenovirus vector-based vaccine, the new one is a promising synthetic vaccine based on peptide", the Russian government said.

We now need to increase production of the first vaccine and the second vaccine, Putin said. "This means we may know whether or not our vaccine is effective by the end of October", Bourla said.

Sputnik V, which was developed by Gamaleya Institute in Moscow, was licensed for use in Russian Federation in August.

There are now 42 vaccines for COVID-19 in clinical trials, the researchers noted.

An advanced study involving tens of thousands of volunteers that is necessary to establish safety and effectiveness of the vaccine is scheduled to start in November or December.

Golikova noted that the trials will include 150 volunteers aged above 60, suggesting that EpiVacCorona might be suitable for elderly people.